University of Miami, Lockheed Martin team up on patient data technology

Lockheed Martin and the University of Miami Health System and Miller School of Medicine have launched a multi-disciplinary partnership deisgned to leverage emerging healthcare technology for improved patient care.

Lockheed Martin will help the University of Miami Health System manage vast streams of healthcare data, develop predictive models for risk identification and build automated systems that ensure providers have information in near real-time to enhance care for the residents of South Florida, according to a release. 

"While an enormous amount of patient information is available in our electronic medical record, this partnership will help us come up with actionable data that is truly important for the patient the physician is taking care of," said David Seo, MD, UM's chief research information officer and CMIO of the Miller School. "This information should not just be about the patient's past. We need a data environment that can do complex statistical analysis to help us move away from reactive medicine and toward proactive medicine, in which we get to patients before they get sick and prevent the disease from occurring."

The two organizations established a data environment last year, as well as implemented big data analytics and predictive modeling tools, and started to stratify patient data and conduct risk assessments. Going forward, the team plans to enhance these tools and techniques and integrate predictive analytics into the hospital workflow while ensuring that patient data is secure.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.